Process for preparing whole blood reference controls having long term stability
First Claim
1. A process for preparing a whole blood reference control having long term stability for devices using electronic means for whole blood determinations, which comprises the steps of:
- a. removing the plasma from whole blood to obtain packed red blood cells;
b. diluting said packed red blood cells in a preconditioning diluent which includes lactose and a non-ionic surfactant for enhancing the separation of step (d);
c. allowing the dilution of step (b) to stand for a preconditioning period of time and temperature which yields a preconditioning to the red blood cells equivalent to the combination of approximately two days at 22°
C. to 27°
C. for attaining desired red blood cell volume and size distribution width;
d. separating the preconditioned red blood cells from the dilution of step (c); and
e. adding a sufficient amount of the preconditioned red blood cells of step (d) to a media which is an aqueous solution of lactose, compatible bacteriostatic and fungicidal agents, albumen and at least one ingredient selected from the following groups;
(A) Bile salts and cholic acid derivatives; and
(B) Phenothiazine compounds having antihistamine properties,said media being osmotically balanced at a preselected and controlled pH, in a total amount sufficient to act as a cell membrane stabilizer, but insufficient to cause lysing of said red blood cells.
0 Assignments
0 Petitions
Accused Products
Abstract
A process for preparing whole blood reference controls having long term stability up to six months for devices using electronic means for whole blood determinations including platelet count and mean cell volume and red blood distribution width. The preconditioning diluent for the red blood cells consists essentially of an aqueous solution of lactose, sodium azide, and a non-ionic surfactant and is pH buffered and osmolality adjusted. The media of the whole blood control includes lactose, fungicides and antibiotics, and supplementary agents including purine nucleosides. It also includes additional components which alter red blood cell membranes including bile salts and cholic acid derivatives, phenothiazine compounds and the salts thereof having antihistamine properties, and 4-aminobenzoic acid ester derivatives and their salts having local anesthetic properties. In the process, the red blood cells are separated from the whole blood and preconditioned by the diluent to attain desired size distribution width and volume. The preconditioned red blood cells then are mixed in the media in suitable number for yielding the desired cell count for the whole blood reference control.
79 Citations
10 Claims
-
1. A process for preparing a whole blood reference control having long term stability for devices using electronic means for whole blood determinations, which comprises the steps of:
-
a. removing the plasma from whole blood to obtain packed red blood cells; b. diluting said packed red blood cells in a preconditioning diluent which includes lactose and a non-ionic surfactant for enhancing the separation of step (d); c. allowing the dilution of step (b) to stand for a preconditioning period of time and temperature which yields a preconditioning to the red blood cells equivalent to the combination of approximately two days at 22°
C. to 27°
C. for attaining desired red blood cell volume and size distribution width;d. separating the preconditioned red blood cells from the dilution of step (c); and e. adding a sufficient amount of the preconditioned red blood cells of step (d) to a media which is an aqueous solution of lactose, compatible bacteriostatic and fungicidal agents, albumen and at least one ingredient selected from the following groups; (A) Bile salts and cholic acid derivatives; and (B) Phenothiazine compounds having antihistamine properties, said media being osmotically balanced at a preselected and controlled pH, in a total amount sufficient to act as a cell membrane stabilizer, but insufficient to cause lysing of said red blood cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification
-
- Resources
-
Current AssigneeCoulter Electronics, Inc.
-
Original AssigneeCoulter Electronics, Inc.
-
InventorsCrews, Harold R., Ledis, Stephen L., Chastain, David L. Jr.
-
Primary Examiner(s)Gron, Teddy S.
-
Application NumberUS06/292,091Time in Patent Office454 DaysField of Search252/408, 23/230 B, 424/2, 424/3, 424/101, 435/4US Class Current436/10CPC Class CodesG01N 2496/05 containing blood cells or p...G01N 33/96 involving blood or serum co...Y10T 436/101666 Particle count or volume st...Y10T 436/105831 Protein or peptide standard...
